Renalytix Plc (NASDAQ:RNLX) Sees Large Decline in Short Interest

Renalytix Plc (NASDAQ:RNLX) was the target of a significant drop in short interest during the month of August. As of August 31st, there was short interest totalling 99,600 shares, a drop of 45.6% from the August 15th total of 183,000 shares. Based on an average daily trading volume, of 2,170,000 shares, the days-to-cover ratio is currently 0.0 days.

Institutional Trading of Renalytix

An institutional investor recently bought a new position in Renalytix stock. Levin Capital Strategies L.P. bought a new stake in shares of Renalytix Plc (NASDAQ:RNLX) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 555,000 shares of the company’s stock, valued at approximately $128,000. Levin Capital Strategies L.P. owned 0.72% of Renalytix at the end of the most recent reporting period. Hedge funds and other institutional investors own 9.92% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $3.00 target price on shares of Renalytix in a research note on Friday, July 12th.

Renalytix Trading Down 6.4 %

Shares of NASDAQ:RNLX opened at $0.28 on Friday. Renalytix has a twelve month low of $0.22 and a twelve month high of $2.41. The company has a 50-day moving average price of $0.33 and a two-hundred day moving average price of $0.56.

Renalytix Company Profile

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score.